In occlusion/occlusion-like syndromes affecting both periphery and brain (portal hypertension, caval hypertension, intracranial hypertension), BPC-157 simultaneously normalized blood pressure disturbances, healed gastrointestinal and liver lesions, minimized brain lesions and hemorrhage, prevented thrombosis, and preserved neurological function
This margin of safety provides reassurance, though caution remains appropriate given the limited formal human studies
It aims to dissect the molecular pathways, evaluate the animal model data, and critically assess the state of human research to equip clinicians with a balanced and actionable perspective
GHK-Cu Application: Apply copper peptide serum immediately after microneedling while channels remain open
Following a recent update by HHS leadership, BPC-157 was officially removed from the restricted Category 2 list in mid-April
Korenevsky AV, Milyutina YP, Bukalyov AV, Baranova YP, Vinogradova IA, Arutjunyan AV